Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06561386 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT06561386: Recruiting Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
NCT06561386 is a Phase 3 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 1,000 participants, above the 650-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (54% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06561386, a Phase 3 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Nivolumab
- DRUG Relatlimab
Study Locations (20)
California
- Local Institution - 0112 - Los Angeles
- University of California Davis (UC Davis) Comprehensive Cancer Center - Sacramento
- San Francisco Oncology Associates - San Francisco
- UCLA Hematology/Oncology - Santa Monica - Santa Monica
Florida
- University of Miami Hospital and Clinics, Sylvester Cancer Center - Miami
- Memorial Hospital West - Pembroke Pines
- Florida Cancer Specialists - North - St. Petersburg
- Florida Cancer Specialists - East - West Palm Beach
Kentucky
- Saint Elizabeth Medical Center Edgewood - Edgewood
- Local Institution - 0130 - Lexington
New York
- Local Institution - 0356 - Hawthorne
- Veterans Affairs New York Harbor Healthcare System - New York
Arizona
- Southern Arizona VA Health Care System - Tucson
Illinois
- Affiliated Oncologists, LLC - Chicago Ridge
Kansas
- Local Institution - 0251 - Wichita
Mississippi
- Hattiesburg Clinic Hematology/Oncology - Hattiesburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2032-08-04 |
| Phase | Phase 3 |
What NCT06561386 shows while recruiting
NCT06561386 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 650-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (54% higher).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06561386 names 20 study sites across 12 states, led by California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06561386 about?
NCT06561386 is a clinical study titled "A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%". The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
What is the current status of trial NCT06561386?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2024-10-07. Estimated completion is 2032-08-04.
What conditions does trial NCT06561386 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06561386?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Pemetrexed (DRUG), Nivolumab (DRUG), Relatlimab (DRUG).
Who is sponsoring clinical trial NCT06561386?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06561386 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06561386's enrollment target sits among peer trials
1,000 22nd of 454 higher than 432 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI